0000000000241408

AUTHOR

Sarah Rose

showing 3 related works from this author

Chronic l-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats

2000

Abstract The effect of a unilateral 6-hydroxydopamine (6-OHDA) lesion of the left medial forebrain bundle and 3 weeks treatment with l -DOPA of normal and 6-OHDA lesioned rats on CB1r mRNA expression was investigated by in situ hybridization. A 6-OHDA lesion of nigrostriatal pathway alone, confirmed by the loss of nigral tyrosine hydroxylase mRNA, did not alter CB1r mRNA levels in the dopamine depleted striatum. Similarly, chronic l -DOPA treatment of normal rats had no effect on striatal CB1r mRNA expression. In contrast, chronic l -DOPA treatment of 6-OHDA-lesioned rats significantly increased CB1r mRNA expression in the denervated striatum. These results suggest that the CB1r activity ma…

Malemedicine.medical_specialtyLevodopaanimal structuresTyrosine 3-MonooxygenaseReceptors DrugDopamine Agents-DOPANigrostriatal pathwayStriatumBiologySubthalamic nucleusStriatumLevodopaLesionAdrenergic AgentsDopamineInternal medicinemedicineAnimalsRNA MessengerRats WistarOxidopamineReceptors CannabinoidMedial forebrain bundleHydroxydopamineTyrosine hydroxylaseGeneral NeuroscienceMedial Forebrain BundleParkinson DiseaseCorpus StriatumRatsmedicine.anatomical_structureEndocrinologynervous systemSettore BIO/14 - Farmacologiamedicine.symptomCannabinoid CB1 receptor mRNA6-Hydroxydopaminemedicine.drugNeuroscience Letters
researchProduct

Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induct…

2002

Chronic administration of L-DOPA to MPTP-treated common marmosets induces marked dyskinesia while repeated administration of equivalent antiparkisonian doses of ropinirole and bromocriptine produces only mild involuntary movements. The occurrence of dyskinesia has been associated with an altered balance between the direct and indirect striatal output pathways. Using in situ hybridisation histochemistry, we now compare the effects of these drug treatments on striatal preproenkephalin-A (PPE-A) and adenosine A(2a) receptor mRNA expression as markers of the indirect pathway and striatal preprotachykinin (PPT) mRNA and preproenkephalin-B (PPE-B, prodynorphin) mRNA expression as markers of the d…

MaleDyskinesia Drug-Inducedmedicine.medical_specialtyIndolesCaudate nucleusStriatumIndirect pathway of movementAntiparkinson AgentsLevodopachemistry.chemical_compoundDopamine Uptake InhibitorsParkinsonian DisordersTachykininsInternal medicineNeural PathwaysmedicineAnimalsheterocyclic compoundsRNA MessengerProtein PrecursorsBromocriptineGeneral NeuroscienceMPTPPutamenNeuropeptidesReceptors Purinergic P1CallithrixEnkephalinsMazindoldopamine agonists peptide mRNAs L-DOPA 1-methyl-4-phenyl-1236-tetrahydropyridine primates dyskinesiaBromocriptinenervous system diseasesNeostriatumRopiniroleEndocrinologynervous systemchemistryDyskinesiaSettore BIO/14 - FarmacologiaFemalemedicine.symptommedicine.drugNeuroscience
researchProduct

Increased neuropeptide Y mRNA expression in striatum in Parkinson's disease.

2003

High levels of neuropeptide Y (NPY) are found in basal ganglia where it is co-localised with somatostatin (SOM) and nicotinamide adenine dinucleotide phosphate-diaphorase (NADPH/d) in a population of striatal GABA containing interneurones. Although alterations occur in the levels of various neuropeptides in basal ganglia in Parkinson’s disease (PD), it is not known whether NPY is affected. Using in situ hybridisation immunohistochemistry, we have examined the distribution of NPY mRNA in the caudate nucleus, putamen and nucleus accumbens of normal individuals and patients with PD. NPY mRNA was weakly expressed in the caudate nucleus, putamen and nucleus accumbens in normal individuals with a…

Malemedicine.medical_specialtyIn situ hybridisationPopulationCaudate nucleusNeuropeptideStriatumBiologyNucleus accumbensNucleus AccumbensStriatumCellular and Molecular NeuroscienceNeuropeptide Y (NPY)InterneuronsInternal medicinemental disordersBasal gangliamedicineHumansNeuropeptide YRNA MessengereducationMolecular BiologyAgededucation.field_of_studyPutamenPutamenParkinson DiseaseMiddle AgedNeuropeptide Y receptorhumanitiesCorpus StriatumEndocrinologynervous systemGene Expression RegulationParkinson’s diseaseSettore BIO/14 - FarmacologiaFemaleCaudate NucleusBrain research. Molecular brain research
researchProduct